Slide 1: Investor Presentation December 2018
Alt lade December 2018 INVESTOR PRESENTATION
Slide 2: Important notice and disclaimer
Althea Group Holdings Limited ACN 626 966 943 (Company) has prepared this presentation (Presentation) dated 10 December 2018 to provide current and prospective investors in the Company with an update in relation to the Company, its subsidiaries and their activities. This Presentation contains summar
Slide 3: Board and corporate snapshot
Board ASX Code: AGH Andrew Newbold: Independent Non Exec Chairman Qualified lawyer. Extensive business experience and current director of Supra Capital, a IPO Price: $0.20 Commissioner of the AFL and director of Golf Australia Current Share Price: $0.2051 Joshua Fegan: CEO / Managing Director Market
Slide 4: >= [ — =< = = — (J)
>= [ — =< = = — (J)
Slide 5: Strong month-on-month patient and prescriber growth
• Strong month-on-month patient and prescriber growth: • 214 patients prescribed Althea medicinal cannabis products from May 2018 with average month-on-month increase of 174% • 70 Healthcare Providers (HCPs) from May 2018 with average month-on- month increase of 185% • 1,832 total SAS B application
Slide 6: Large shipment of five medicinal cannabis products scheduled
• Althea scheduled to receive a large shipment of its five medicinal cannabis products (four oils and one dried flower) by 15th December 2o18 • Planning is underway to secure up to 12 months future inventory in Australia for supply until Althea’s own production commences in early 2020 • New Products
Slide 7: Althea Concierge patient / doctor portal launched September 2018
• Althea Concierge patient / doctor portal – launched September 2018 • 285 Patient registrations • 132 HCP registrations • Regular updates of the Althea Concierge platform – next major update to feature integration with the official TGA portal • Increased user uptake will be a particular focus in 1H
Slide 8: Althea granted all required ODC licenses
• Althea has been granted all required Office of Drug Control (ODC) licenses including Import, Cultivation, Manufacturing and Export licenses • Design of ODC approved state-of-the-art production facility complete • Planning permit lodged November 2018 • Expected completion of production facility Q4,
Slide 9: Making a Difference
MAKING A DIFFERENCE
Slide 10: Response to the medicinal cannabis patient access dilemma
• Althea’s response to the medicinal cannabis patient access dilemma: • Evidence-based Medical Education • Althea representatives work with doctors (specialists, GPs, psychiatrists etc.) face-to-face, helping them understand Althea medicinal cannabis as a treatment option for their patients • Regula
Slide 11: Patient case studies
• Patient X: 17 year old female, 5 years post surgery • Indications: Chronic pain, spasms, limited physical ability (could not go up stairs) • Progress: 1 month post commencing Althea medicinal cannabis dancing and sleeping in her own second floor bedroom • Patient Y: 5 year old female • Indication:
Slide 12: More Information
MORE INFORMATION
Slide 13: Patient and HCP registrations over time
250 214 197 200 150 126 100 80 53 50 34 67 70 18 46 4 26 30 0 17 3 May-18 12 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Patient HCP's
Slide 14: SAS B application numbers
600 568 500 400 329 300 231 238 200 188 132 146 89 100 60 54 37 0 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Based on SAS B Application numbers released by the TGA: https://www.tga.gov.au/access-medicinal-cannabis-products-1
Slide 15: Althea commenced importing and supplying medicinal cannabis in May 2018
• Althea commenced importing and supplying medicinal cannabis to patients in Australia in May 2018 • Althea maintains an extensive medical education program, employing medical science liaisons all over the country, to assist Healthcare Providers (HCP) with prescribing Althea medicinal cannabis • Alt
Slide 16: Current oil and dried flower products
• Althea currently sells four oil products and one dried flower product to eligible patients in Australia • The benefits of Althea’s medicinal cannabis oil include: • Providing patients with a slower and longer release of medicinal cannabis which is beneficial for treatment of specific conditions •
Slide 17: Additional gel capsule and spray products
• Althea will add two additional products, gel capsules and a 15ml spray, to its product range in the first half of 2019 • The benefits of Althea’s medicinal cannabis gel capsules include: • Controlled dosage in a familiar preparation • A slower and longer onset, beneficial for treatment of specific
Slide 18: Althea Concierge patient registrations and platform
• 285 patient registrations and 132HCP registrations since September 2018, creating a growing channel that is proactively engaged with Althea, its products and educational content • Althea intends to accelerate its sales efforts to supply more medicinal cannabis products to eligible patients seeking
Slide 19: ODC licences granted
• The Office of Drug Control (ODC) has granted Althea the full suite of applicable licenses in Australia for it to execute its business plan, including: • Cultivation and Manufacture licence – providing Althea with the right to grow and manufacture its own medicinal cannabis products at its upcoming
Slide 20: Facility design and permit timeline
• Design and drawings complete • Planning and Building permit lodged November 2018 • Expected completion Q4,2019
Slide 21: 30 year lease and Victorian production facility
• Althea has entered into a 30 year lease for a 10-acre parcel of land in Victoria and has received its Office of Drug Control licences for cultivation and manufacture • Althea plans to grow and manufacture its own high-quality medicinal cannabis for supply to eligible patients in Australia. Althea
Slide 22: Export legalisation of medicinal cannabis
• The export of medicinal cannabis products from Australia was legalised in February 2018 through the Narcotic Drugs Amendment (Cannabis) Regulations 2018. The primary driver for the legalisation of exports is to enhance the viability of the medicinal cannabis industry within Australia, in turn impr